Bifunctional enzyme for degrading vomitoxin and application thereof
By connecting dehydrogenase and aldehyde ketone reductase fragments, the problem of incomplete degradation of vomit toxin is solved, and the efficient degradation of vomit toxin into a low-toxic form is achieved, avoiding the introduction of new pollutants, and improving the Food and feed safety.
Patent Information
- Application Number
- CN202310662047.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-05
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art When removing mycotoxins from food or feed, especially vomiting toxins, there are problems such as incomplete detoxification, loss of nutrients and introduction of new contamination, making it difficult to achieve efficient, specific and thorough degradation.
Develop a bifunctional enzyme formed by ligation of dehydrogenase and aldehyde ketone reductase fragments that can degrade vomittoxin into 3-keto-DON and 3-epi-DON under specific pH and temperature conditions to achieve its toxicity reduce.
This dual-function enzyme can completely degrade vomittoxin in a short time and convert it into an almost non-toxic isomeric form, avoiding the introduction of new pollutants and improving degradation efficiency and safety.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure HDA0004269726300000011
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of genetic engineering and enzyme engineering; more specifically, the present invention relates to a bifunctional enzyme for degrading vomitoxin, a preparation method thereof and an application thereof in degrading vomitoxin into almost non-toxic isomeric forms. Background Art
[0002] Mycotoxins are toxic secondary metabolites produced by fungi under certain conditions, which can cause harm to plants, animals and humans. They are mainly produced by Aspergillus, Fusarium, Penicillium, Alternaria and Corynebacterium. There are about 400 types of mycotoxins reported so far, mainly including aflatoxins, Fusarium, patulin, Alternaria toxins, fumonisins, etc. According to the Food and Agriculture Organization of the United Nations, about 25% of the grains produced in the world are contaminated by mycotoxins.
[0003] Deoxynivalenol (DON) is a tetracyclic epoxy sesquiterpene belonging to the B-type trichothecenes. Deoxynivalenol poses a threat to the health of both humans and animals, and can cause gastrointestinal discomfort, vomiting, dizziness, headache, abdominal pain and diarrhea in humans and animals. Not only that, it can also damage the immune and reproductive functions of humans and animals. The Food and Agriculture Organization of the United Nations and the World Health Organization have identified DON as one of the most dangerous naturally occurring food contaminants. According to GAKRB2761-2017, the limit standard for deoxynivalenol in food is 1000 μg / kg. Studies have shown that deoxynivalenol is commonly contaminated in grains and their products. In some areas, the detection of deoxynivalenol in grains and by-products used as feed raw materials found that the detection rate of deoxynivalenol was greater than 90%, and the excess rate was 11.1% to 31.3%. Therefore, it is necessary to pay attention to the contamination of deoxynivalenol.
[0004] At present, the methods for removing mycotoxins from food or feed can be divided into three categories: physical, chemical and biological detoxification. Although the traditional physical and chemical methods have achieved certain results, their application and promotion are limited by problems such as incomplete detoxification, loss of nutrients and introduction of new pollution. Finding a method with specific, efficient and thorough detoxification ability is a bottleneck in this field.
[0005] Regarding the detoxification methods of vomitoxin, they mainly include physical methods, chemical methods and biological methods. The physical detoxification method mainly removes fungal toxins through methods such as washing, boiling, blanching, cooking, and baking. The chemical detoxification method mainly uses acids, alkalis, oxidants and reductants to remove fungal toxins. Although the above two methods have certain effects, problems such as incomplete detoxification and the introduction of new pollution have limited the application of these methods. The biological method needs to be optimized and selected in order to obtain active proteins suitable for efficient and large-scale degradation. Summary of the invention
[0006] The object of the present invention is to provide a bifunctional enzyme for degrading vomitoxin and application thereof.
[0007] In a first aspect of the present invention, a method for degrading vomitoxin is provided, the method comprising:
[0008] (1) connecting a dehydrogenase (depA) fragment and an aldehyde-keto reductase (AKRB2) fragment to form a bifunctional enzyme with synergistic effects;
[0009] (2) Using the bifunctional enzyme with synergistic effects described in (1) or a system containing the enzyme to treat vomitoxin or an object (system) containing the vomitoxin, the vomitoxin is degraded into 3-keto-DON and 3-epi-DON.
[0010] In one or more preferred embodiments, the pH value of the reaction system during degradation is in the range of 5-8.
[0011] In one or more preferred embodiments, during the degradation, the temperature of the reaction system is 30-60°C (eg, 35°C, 40°C, 50°C, 55°C, etc.).
[0012] In one or more preferred embodiments, during the degradation, DON is completely degraded within 4±3h (preferably 4±2h, more preferably 4±1h) at 40±10°C, preferably 40±5°C, and more preferably 40±3°C, and the vomitoxin is degraded into 3-keto-DON and 3-epi-DON.
[0013] In one or more preferred embodiments, the system containing the enzyme includes a cell system expressing the enzyme, a cell culture system, a cell lysate system, etc.; when the cell expresses the enzyme by secretion, the system containing the enzyme includes the cell supernatant or a concentrated solution / dilution solution / processed product of the supernatant, etc.
[0014] In one or more preferred embodiments, the method for degrading DON is an in vitro method.
[0015] In one or more preferred embodiments, the method for degrading DON is a method that is not directly intended to treat a disease.
[0016] In one or more preferred embodiments, the object (system) containing vomitoxin can be a non-animal / non-human object, including a place, a container, in vitro food, in vitro feed, a plant, etc.
[0017] In one or more preferred embodiments, (a) the bifunctional enzyme comprises, from the amino terminus to the carboxyl terminus, the dehydrogenase fragment, the aldehyde-keto reductase fragment; preferably, the two are connected by a connecting peptide.
[0018] In one or more preferred embodiments, (b) the bifunctional enzyme comprises, from the amino terminus to the carboxyl terminus, the aldehyde-keto reductase fragment, the dehydrogenase fragment; preferably, the two are connected by a connecting peptide.
[0019] In one or more preferred embodiments, the connecting peptide comprises a flexible linker protein.
[0020] In one or more preferred embodiments, in (a), the amino acid sequence of the dehydrogenase fragment is as shown at positions 1 and 8 to 592 in SEQ ID NO:8; the amino acid sequence of the aldehyde-keto reductase fragment is as shown at positions 615 to 897 in SEQ ID NO:8; preferably, the amino acid sequence of the connecting peptide is as shown at positions 593 to 614 in SEQ ID NO:7; or
[0021] In one or more preferred embodiments, in (b), the amino acid sequence of the dehydrogenase fragment is as shown at positions 1 and 8 to 290 in SEQ ID NO:6; the amino acid sequence of the aldehyde-keto reductase fragment is as shown at positions 301 to 885 in SEQ ID NO:6; preferably, the amino acid sequence of the connecting peptide is as shown at positions 291 to 300 in SEQ ID NO:6.
[0022] In one or more preferred embodiments, in the bifunctional enzyme having synergistic effect, the aldehyde-keto reductase fragment and the dehydrogenase fragment (preferably also including between them and the connecting peptide) are connected by peptide bonds.
[0023] In one or more preferred embodiments, the amino acid sequence of the bifunctional enzyme is shown in SEQ ID NO:8 or SEQ ID NO:6.
[0024] In one or more preferred embodiments, the bifunctional enzyme is encoded by a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO:7 or SEQ ID NO:5.
[0025] In one or more preferred embodiments, the amino acid sequence of the bifunctional enzyme is shown in SEQ ID NO:8.
[0026] In one or more preferred embodiments, the bifunctional enzyme as shown in SEQ ID NO: 8 has a high expression efficiency / expression amount.
[0027] In another aspect of the present invention, a bifunctional enzyme with synergistic effects is provided, comprising the following proteins linked to each other: a dehydrogenase fragment, and an aldehyde-keto reductase fragment, both of which are operably linked.
[0028] In another aspect of the present invention, a nucleic acid molecule is provided, wherein the nucleic acid molecule encodes any of the above-mentioned bifunctional enzymes with synergistic effects.
[0029] In one or more preferred embodiments, the nucleotide sequence of the nucleic acid is shown as SEQ ID NO:7 or SEQ ID NO:5.
[0030] In another aspect of the present invention, a vector is provided, wherein the vector contains the nucleic acid molecule.
[0031] In one or more preferred embodiments, the vector is a prokaryotic expression vector.
[0032] In one or more preferred embodiments, the vector uses pET-28a as a backbone vector.
[0033] In another aspect of the present invention, a genetically engineered cell is provided, wherein the cell contains the vector or the nucleic acid molecule is integrated into its genome.
[0034] In one or more preferred embodiments, the cell is a prokaryotic cell; preferably an Escherichia coli cell.
[0035] In another aspect of the present invention, a method for preparing any of the above-mentioned bifunctional enzymes with synergistic effects is provided, comprising: (1) culturing the genetically engineered cells; and (2) expressing and isolating the bifunctional enzymes with synergistic effects.
[0036] In another aspect of the present invention, there is provided a use of any of the above-mentioned bifunctional enzymes with synergistic effects for degrading vomitoxin (DON).
[0037] In another aspect of the present invention, there is provided a use of any of the above-mentioned bifunctional enzymes with synergistic effects for preparing a composition for degrading vomitoxin.
[0038] In another aspect of the present invention, a composition for degrading vomitoxin is provided, the composition comprising: any of the above described bifunctional enzymes with synergistic effects; and (ii) a biologically (including food) acceptable carrier.
[0039] In another aspect of the present invention, a kit for degrading vomitoxin is provided, wherein the kit contains any of the above-mentioned bifunctional enzymes with synergistic effects; or contains the above-mentioned composition.
[0040] Other aspects of the present invention will be apparent to those skilled in the art in view of the disclosure herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0041] Figure 1A , schematic diagram of the construction of the prokaryotic expression vector PET22-AKRB2-DepA.
[0042] Figure 1B , solubility analysis of the bifunctional enzyme B2A.
[0043] Figure 2 , Schematic diagram of the elements of the prokaryotic expression vector PET22-AKRB2-DepA.
[0044] Figure 3 , PCR identification of the connection between the fragment and the plasmid.
[0045] Figure 4 , SDS-PAGE electrophoresis results of prokaryotic expressed and purified B2A protein.
[0046] Figure 5 , SDS-PAGE electrophoresis results of prokaryotic expression of APB protein. The three lanes from left to right are APB protein induced by 0.2mM IPTG, 0.4mM IPTG and 0.8mM IPTG.
[0047] Figure 6. B2A has a catalytic effect on DON. The DON content in the solution was detected by HPLC-UV. A: The test solution contained 34 μM DON as a standard, B: B2A crude enzyme treated 34 μM DON for 4 h. Figure 7. High-resolution identification of DON degradation products. TripleTOF 6600 high-resolution LC / MS identification of DON degradation products. A: 295.1 channel image of degradation products, B: 293.1 channel image of degradation products. DETAILED DESCRIPTION
[0048] After in-depth research, the inventors have revealed for the first time a synergistic bifunctional enzyme, which includes a dehydrogenase (depA) fragment and an aldehyde-keto reductase (AKRB2) fragment. The synergistic bifunctional enzyme can be effectively expressed, and after expression, it can form a protein spatial structure that is more conducive to degradation, has ideal biological activity, and can achieve complete degradation of vomitoxin.
[0049] the term
[0050] As used in this article, "bifunctional enzyme with synergistic effect", "bifunctional enzyme", "bifunctional protein (peptide / polypeptide)", "B2A", "protease B2A" and the like are used interchangeably and refer to a protein composed of an aldehyde-keto reductase fragment and a dehydrogenase fragment; preferably, they are connected by a chemical bond (such as a peptide bond).
[0051] As used herein, "degradation" refers to the modification of the structure of the target compound, conversion of the target compound into another compound, or modification of the target compound. In the present invention, the purpose is to reduce the toxicity of the target compound, so the "degradation" refers to the conversion of a highly toxic compound into a less toxic compound through the action of an enzyme.
[0052] As used herein, "operably linked" or "operably linked to" refers to a situation in which certain portions of a linear DNA sequence are able to affect the activity of other portions of the same linear DNA sequence. For example, if a promoter controls the transcription of a coding sequence, it is operably linked to a coding sequence.
[0053] As used herein, "biologically acceptable carrier" refers to a solvent, suspending agent or excipient, etc., which is used to deliver the synergistic bifunctional enzyme of the present invention to an object to be treated (including food and feed), and is environmentally friendly or harmless to humans and animals, with controllable toxicity and side effects. The carrier can be liquid or solid, preferably a carrier that can maintain the biological activity of the synergistic bifunctional enzyme of the present invention to a high degree.
[0054] As used herein, the terms “containing”, “having” or “including” include “comprising”, “mainly consisting of…”, “substantially consisting of…”, and “consisting of…”; “mainly consisting of…”, “substantially consisting of…” and “consisting of…” are subordinate concepts of “containing”, “having” or “including”.
[0055] Bifunctional enzymes with synergistic effects
[0056] The present invention provides a synergistic bifunctional enzyme, which comprises a dehydrogenase fragment and an aldehyde-keto reductase fragment, which are operatively connected. Preferably, the synergistic bifunctional enzyme is an isolated protein, a purified product of recombinant host cell culture or a purified extract; the synergistic bifunctional enzyme can also be present in a mixture, such as in a cell lysate or crude extract.
[0057] The present invention includes derivatives and analogs of the dehydrogenase fragment or aldehyde-keto reductase fragment. As used herein, the terms "derivative" and "analog" refer to polypeptides that substantially retain the same biological function or activity as the dehydrogenase fragment or aldehyde-keto reductase fragment of the present invention. The polypeptide fragment, derivative or analog of the present invention may be (i) a polypeptide having one or more conservative or non-conservative amino acid residues (preferably conservative amino acid residues) substituted, and such substituted amino acid residues may or may not be encoded by the genetic code, or (ii) a polypeptide having a substitution group in one or more amino acid residues, or (iii) a polypeptide formed by fusion of a mature polypeptide with another compound (such as a compound that prolongs the half-life of the polypeptide, such as polyethylene glycol), or (iv) a polypeptide formed by fusion of an additional amino acid sequence to the polypeptide sequence (such as a leader sequence or secretory sequence or a sequence or proprotein sequence used to purify the polypeptide, or a fusion protein formed with an antigen IgG fragment).
[0058] In the present invention, the term "dehydrogenase fragment" refers to a polypeptide comprising the amino acid sequence shown at positions 8 to 290 in SEQ ID NO: 6. The term also includes variant forms of the polypeptide having the amino acid sequence shown at positions 8 to 290 in SEQ ID NO: 6 and having the same function as the dehydrogenase fragment. These variant forms include (but are not limited to): deletion, insertion and / or substitution of one or more (usually 1-20, preferably 1-15, more preferably 1-10, more preferably 1-5, more preferably 1-2) amino acids, and addition or deletion of one or several (usually within 20, preferably within 10, more preferably within 5) amino acids at the C-terminus and / or N-terminus. For example, in the art, when substitution is performed with amino acids with similar or similar properties, the function of the polypeptide is often not changed. For example, adding or deleting one or several amino acids at the C-terminus and / or N-terminus often does not change the function of the polypeptide. Therefore, the term also includes active fragments and active derivatives of the dehydrogenase fragment. For example, the mutation may occur outside the conserved functional domain (the functional domain that degrades toxin) of the polypeptide having the amino acid sequence shown at positions 8 to 290 in SEQ ID NO:6.
[0059] In the present invention, the term "aldehyde-keto reductase fragment" refers to a polypeptide comprising the amino acid sequence shown at positions 301 to 885 in SEQ ID NO: 6. The term also includes variant forms of the polypeptide having the amino acid sequence shown at positions 301 to 885 in SEQ ID NO: 6 and having the same function as the aldehyde-keto reductase fragment. These variant forms include (but are not limited to): deletion, insertion and / or substitution of one or more (usually 1-20, preferably 1-15, more preferably 1-10, more preferably 1-5, more preferably 1-2) amino acids, and addition or deletion of one or several (usually within 20, preferably within 10, more preferably within 5) amino acids at the C-terminus and / or N-terminus. For example, in the art, when substitution is performed with amino acids with similar or similar properties, the function of the polypeptide is often not changed. For example, adding or deleting one or several amino acids at the C-terminus and / or N-terminus often does not change the function of the polypeptide. Therefore, the term also includes active fragments and active derivatives of the aldehyde-keto reductase fragment. For example, the variation may occur outside the conserved functional domain (functional domain that degrades the toxin) of the polypeptide of the amino acid sequence shown at positions 301 to 885 in SEQ ID NO:6.
[0060] It should be understood that the present invention also includes proteins with higher homology to the aldehyde-keto reductase fragment or dehydrogenase fragment, such as having more than 80%, such as 85%, 90%, 95%, or even 98% sequence identity. Methods and tools for comparing sequence identity are also well known in the art, such as BLAST.
[0061] The aldehyde-keto reductase fragment and the dehydrogenase fragment of the present invention are connected or coupled to each other by a chemical bond; the chemical bond is a covalent bond or a non-covalent bond. As a preferred embodiment of the present invention, the aldehyde-keto reductase fragment and the dehydrogenase fragment are connected by a chemical bond; more preferably, the chemical bond is a peptide bond.
[0062] As a preferred embodiment of the present invention, the synergistic bifunctional enzyme comprises, from the amino end to the carboxyl end, a dehydrogenase fragment and an aldehyde-keto reductase fragment. In a more preferred embodiment, the dehydrogenase fragment is located at the N-terminus of the bifunctional enzyme, which has a higher expression efficiency / expression amount.
[0063] The aldehyde-keto reductase fragment and the dehydrogenase fragment can be directly connected, preferably through a polypeptide linker (connector peptide). The linker includes, for example, 1-50 amino acids; preferably 1-30 or 2-20 amino acids. As a preferred embodiment of the present invention, the aldehyde-keto reductase fragment and the dehydrogenase fragment are directly connected.
[0064] As a preferred embodiment of the present invention, the connecting peptide is a connecting peptide having an amino acid sequence as shown at positions 593 to 614 in SEQ ID NO: 7 or as shown at positions 291 to 300 in SEQ ID NO: 6; the former is more preferred.
[0065] On the other hand, the present invention also provides the isolated nucleic acid of the bifunctional enzyme with synergistic effect described in coding, and can also be its complementary strand.Any nucleic acid with synergistic effect described in coding is all applicable to the present invention.The sequence mentioned in the example below is all applicable to the method of the present invention.
[0066] The DNA sequence encoding the synergistic bifunctional enzyme of the present invention can be synthesized in its entirety, or the DNA sequences encoding the amino acids of the aldehyde-keto reductase fragment and the dehydrogenase fragment can be obtained separately by PCR amplification, and then spliced together to form the DNA sequence encoding the synergistic bifunctional enzyme of the present invention.
[0067] The present invention also provides a vector comprising a nucleic acid molecule encoding the synergistic bifunctional enzyme. The vector may also comprise an expression control sequence operably linked to the sequence of the nucleic acid molecule to facilitate the expression of the synergistic bifunctional enzyme.
[0068] A variety of suitable vectors can be used in the present invention, such as some vectors used for cloning and expression of bacteria, fungi, yeast and mammalian cells, for example, as described in Pouwels et al., Cloning Vectors: A Laboratory Manual. Preferably, the expression vector is an expression vector suitable for Escherichia coli.
[0069] In addition, recombinant cells containing a nucleic acid sequence encoding the bifunctional enzyme having a synergistic effect are also included in the present invention.
[0070] In the present invention, the term "host cell" includes prokaryotic cells and eukaryotic cells. Commonly used prokaryotic host cells include Escherichia coli, Bacillus subtilis, etc. Commonly used eukaryotic host cells include yeast cells, insect cells and mammalian cells. In the present invention, preferably Escherichia coli cells (E.coli), such as Escherichia coli BL21 (DE3) or HMS174 (DE3).
[0071] The method for producing the synergistic bifunctional enzyme of the present invention is also included in the present invention. The method comprises cultivating a recombinant cell containing a synergistic bifunctional enzyme encoding nucleic acid. The method may also comprise separating and / or purifying the synergistic bifunctional enzyme.
[0072] The bifunctional enzyme with synergistic effect prepared as above can be purified to have substantially uniform properties, for example, to appear as a single band on SDS-PAGE electrophoresis.
[0073] In a specific embodiment of the present invention, a method for preparing a bifunctional enzyme for a two-step reaction of degrading DON to 3-epi-DON is provided, and a PET22-AKRB2-DepA recombinant plasmid is obtained using a one-step cloning kit, and B2A is obtained through a prokaryotic expression system. The prokaryotic expression system is Escherichia coli (E. coli BL21 (DE3)), which is used as a host cell, and the host cells in the logarithmic growth phase are treated with the CaCl2 method to prepare competent cells, and the successfully constructed PET22-AKRB2-DepA recombinant plasmid is used to transform the host competent cells to obtain a recombinant bacterium that can express a vomitoxin-degrading enzyme. In a more specific embodiment, the inventors use a flexible linker to connect the AKRB2 and DepA nucleotide sequences, and add a 6×His tag after the start codon. The obtained fusion fragment sequence is shown in SEQ ID NO:5, and the protein sequence encoded by the fusion gene is shown in SEQ ID NO:6.
[0074] The protein encoding PET22-AKRB2-DepA was obtained by prokaryotic expression, and the crude enzyme solution was reacted with DON in a suitable buffer, and the content of DON in the solution was measured by high-performance liquid chromatography (HPLC) and LC-MS. The results showed that the recombinant protein B2A can efficiently degrade DON to 3-keto-DON in a short time and further convert it into 3-epi-DON with lower toxicity.
[0075] In a more preferred embodiment, by replacing the connecting peptide and the plasmid, the inventors obtained the encoded protein of PET28 a-DepA-AKRB2, which greatly improved the expression of the bifunctional enzyme.
[0076] Application of bifunctional enzymes with synergistic effects
[0077] The present invention also provides the application of bifunctional proteins B2A and APB in degrading DON, which can efficiently convert DON into almost non-toxic isomeric forms in a short time. The present invention is the first to establish a bifunctional enzyme that can simultaneously degrade DON to 3-keto-DON and 3-keto-DON to 3-epi-DON.
[0078] The invention obtains a synergistic bifunctional enzyme with ideal activity, good selectivity, and no residual toxicity. It can be suitable for recombinant expression under the conditions of Escherichia coli expression and has wide application potential.
[0079] According to the new discovery of the inventors, the use of the bifunctional enzyme with synergistic effect of the present invention includes: degrading vomitoxin (DON); or preparing a composition for degrading vomitoxin. At the same time, it should be understood that the bifunctional enzyme with synergistic effect of the present invention can also be used to degrade other toxins that are similar to vomitoxin in chemical structure, and such applications should also be included in the present invention.
[0080] After obtaining the bifunctional enzyme with synergistic effect of the present invention, according to the teaching of the present invention, the skilled person can conveniently apply the enzyme to play the role of degrading vomitoxin. In one embodiment, a method for degrading vomitoxin is provided, comprising: using the bifunctional enzyme with synergistic effect of the present invention or the composition for inhibition. In another embodiment, a method for degrading vomitoxin is provided, comprising: introducing a polynucleotide encoding the bifunctional enzyme polypeptide with synergistic effect of the present invention into a genetically engineered cell, the genetically engineered cell can be propagated on a large scale, applying the genetically engineered cell or its processed product to an object (such as but not limited to: food, beverage or feed), utensils (such as food or feed containers) or places (such as some food storage, food processing, feed processing, animal breeding or plant cultivation places) that needs detoxification treatment, thereby exerting an inhibitory effect.
[0081] The inventors first used an E. coli expression system to express a synergistic bifunctional enzyme that degrades vomitoxin into non-toxic chemicals. Compared with the degradation using only a single enzyme, the synergistic bifunctional enzyme has a better application prospect. The connection and use of multiple proteins generally cannot achieve good activity due to changes in spatial structure, especially for some relatively long proteins; while the synergistic bifunctional enzyme of the present invention has a very ideal detoxification effect.
[0082] It should be understood that, under the teaching of the present invention, there are also various application modes of the bifunctional enzyme with synergistic effects of the present invention, which should all be included in the present invention.
[0083] Composition / Preparation / Kit
[0084] The present invention provides a composition, which contains an effective amount of a bifunctional enzyme with synergistic effects and a balance of a biologically acceptable carrier.
[0085] The dosage form of the composition can be various, including but not limited to: aqueous solution, suspension, sprayable solution, emulsion, lyophilized agent, oily or aqueous dispersion, powder, granule, wettable powder, emulsifiable concentrate or microcapsule, etc.
[0086] It should be understood that any dosage form is desirable as long as the bifunctional enzyme with synergistic effect described in the present invention can be delivered to an object (such as, but not limited to, food, beverage or feed), a utensil (such as a food or feed container) or a place (such as some food storage, food processing, feed processing, animal breeding or plant cultivation sites) that needs detoxification treatment while maintaining all or part of its activity. Preferred dosage forms are those that are easy to deliver. As some preferred modes, the composition can be a liquid, a spray, an aerosol or a lyophilized agent.
[0087] The active ingredient (polypeptide) content in the concentrated composition is relatively high, such as 6-90% or 10-90% of the synergistic bifunctional enzyme content, while the active ingredient content in the diluted composition is relatively low, such as 0.00005-5%. In addition, other suitable ingredients may also be included, such as various biologically acceptable carriers listed above.
[0088] In some necessary cases, the composition of the present invention may also contain other active toxin degrading components to achieve the co-degradation or attenuation of multiple toxins through one use.
[0089] The synergistic bifunctional enzyme of the present invention, the vector or host cell containing the same, or the composition containing the same or the host cell thereof, may also be contained in a container or a kit. Preferably, the kit also includes instructions for use, etc., to facilitate use by those skilled in the art.
[0090] The main advantages of the present invention are:
[0091] Most of the currently known degradation enzymes are one-step reactions, and there are few enzymes that can perform two-step reactions at the same time. The present invention is the first to obtain an enzyme that can perform two-step reactions (degrading DON to 3-keto-DON and further converting it to 3-epi-DON with lower toxicity) to convert DON into a product with lower toxicity, with high degradation efficiency. Compared with single-functional enzymes, it has more application prospects.
[0092] The bifunctional enzyme with synergistic effect of the present invention is simple to prepare, easy to operate, has clear gene products, and is suitable for large-scale production.
[0093] The method of the present invention is based on a biological detoxification method, which utilizes biological enzymes to degrade vomitoxin into non-toxic or low-toxic compounds without introducing new pollutants.
[0094] The present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually carried out according to conventional conditions such as those described in J. Sambrook et al., Molecular Cloning Experiment Guide, 3rd Edition, Science Press, or according to the conditions recommended by the manufacturer.
[0095] Example 1: Cloning of genes encoding bifunctional enzyme B2A and bifunctional enzyme APB and construction and transformation of prokaryotic expression vectors
[0096] The cloning of the genes encoding the bifunctional enzymes B2A and APB first provided the AKRB2 and depA gene sequences.
[0097] The AKRB2 gene sequence is as follows (SEQ ID NO: 1):
[0098] ATGAGCGAACCGAACGCGGCTCTGGCGGGTCAGTTCAAAATCGGTGGCGATCTGACCATCAACCGTCTGGGTTTCGGTGCAATGCGTATCACCGGTGAAGGTATCTGGGGTCAGCCGAAAGATGTTGAAGAAGCGCGTCGTGTTCTGCGTCGTCTGAAAGCGCTGGGTGTAAACTTCGTTGACACCGCGGAAAGCTACGGCCCGGAAGTTTCTGAACAGCTGATCGCGGATGAACTGTACCCGTACGATGGTTTCGTTATCGCGACCAAAGCAGGCCTGCAGCGTCCGGGTCCGAACCACTGGGTTCAGGATGGCCGCCCGGAAGTTCTGCGCCGTGGTCTGGAAGCGAGCCTGAAACGTCTGAAAGTTGAACGTATCGACCTGTGGCAGCTGCACCGCATCGATAGCAAAGTTCCGCGTGATGAACAGTTCGCAGCGATCGCAGGCTTCGTTAAAGACGGTCTGGTTCGTCACGTTGGCCTGAGCGAAGTTACCGTGGAAGAAATCGAAGCAGCGCAGAAATACTTCCCGGTTGCTACCATCCAGAACCGCTACAACCTGTTCGACCGTGCGAGCGAAGAAGAACTGGAGTTCTGCGAAGCGAACGCGATCGGCTTCATCCCGTGGGCGCCCCTGGCGTCTGGTCGTGTGGGTGGCCGTCCGGTGCTGGAAGCGGTTGCGCAGCGTCATGGTGCATCTCCGGGTCAAATTGCTCTGGCTTGGATGTTAAAACGTTCTCCGGTTATCTTACCGATTCCGGGTACCGGTAAAGTTGCTCATCTGGAAGAAAACGTTGCTGCCGCTGGTATTACCCTGTCTGAAGGTGATATGGCTGAACTGGAAGGCGCTTCC TAA
[0099] The amino acid sequence of AKRB2 is as follows (SEQ ID NO: 2):
[0100]
[0101] The depA gene sequence is as follows (SEQ ID NO: 3):
[0102] ATGTAA
[0103] The amino acid sequence of depA is as follows (SEQ ID NO: 4):
[0104]
[0105] Preparation of AKRB2 and depA gene sequences: AKRB2 and depA sequences were synthesized by Jinweizhi Biotechnology Co., Ltd. AKRB2 and depA were used as amplification templates, and high-fidelity enzymes Max DNA Polymerase was used to amplify the target gene fragment (purchased from Takara, Japan).
[0106] Amplification primers for AKRB2 (B2A):
[0107] Forward primer (22-AKRB2-5F) (SEQ ID NO: 9):
[0108] 5'-attaattcggatccgaattcgatg catcatcaccatcaccat agcgaaccgaacgcggctctg-3';
[0109] Reverse primer (22-AKRB2-5R) (SEQ ID NO: 10):
[0110] 5'-tgatccccctccgcccgatccaccaccaccggaagcgccttccagttcagcc-3';
[0111] Amplification primers for AKRB2 (APB):
[0112] Forward primer (28-APB-3F) (SEQ ID NO: 13; the underlined sequence is the nucleotide coding sequence of the connecting peptide):
[0113] 5'- gctgaagcaggctggagacgtggaggagaaccctggacct agcgaaccgaacgcggctctg-3'
[0114] Reverse primer (28-APB-3R) (SEQ ID NO: 14):
[0115] 5'-gtggtgctcgagtgcggccgcggaagcgccttccagttcagcc-3'
[0116] Primers for amplification of depA (B2A):
[0117] Forward primer 22-A-3F (SEQ ID NO: 3; the underlined sequence is the Linker protein nucleotide coding sequence):
[0118] 5'- ggtggtggtggatcgggcggagggggatca tctgctccagcttttgctc-3' (SEQ ID NO: 11);
[0119] Reverse Primer 22-A-3R:
[0120] 5'-gtggtgctcgagtgcggccgcttacttggcctctggcaaggcaaag-3' (SEQ ID NO: 12).
[0121] Amplification primers for depA (APB):
[0122] Forward primer (28-APB-5F) (SEQ ID NO: 15):
[0123] 5'-tgggtcgcggatccgaattcATG catcatcaccatcaccat TCTGCTCCAGCTTTTGCTC-3;
[0124] Reverse primer (28-APB-5R) (SEQ ID NO: 16):
[0125] 5'-gtggtgctcgagtgcggccgcttacttggcctctggcaaggcaaag-3'
[0126] 50μL reaction system: 2× PrimerSTAR Max Premix 25μL, 10μM primer 2.5μL each, template 2μL, add ddH2O to a total volume of 50μL. PCR reaction conditions: 98℃ pre-denaturation for 2min; 98℃ 10s, 55℃ 5s, 72℃ 30s, 30-35 cycles, 72℃ extension for 10min. Obtain AKRB2 and depA fragments as above, cut gel and recover for later use.
[0127] Expression vector construction: EcoR I and Not I (purchased from Takara, Japan) were used to double-digest the prokaryotic expression vector pET-22b (purchased from Novagen, USA). 50μL reaction system: 10×Q.cut buffer 5μL, plasmid 5μg, EcoR I and Not I 1μL each, add ddH2O to a total volume of 50μL, and digest at 37℃ for 1h. Agarose gel electrophoresis was used to detect the digestion effect and the required linearized plasmid was recovered by gel cutting. The digested pET22b plasmid was mixed with AKRB2 and depA according to the following 10μL system: AKRB2 17ng, depA 35ng, pET22b or pET28a 104ng, 5×CE MultiS Buffer 2μL, MultiS 1μL, add ddH2O to a total volume of 10μL, incubate at 37℃ for 30min, then immediately put on ice for 5min, and the ligation product is directly used for E. coli transformation. Figure 2 Schematic diagram of the construction of the prokaryotic expression vector PET22-AKRB2-DepA and a schematic diagram of its elements.
[0128] Transformation of E. coli and sequencing: The successfully constructed ligation product pET-22b-AKRB2-depA was directly transformed into E. coli DH5α competent cells, spread on Amp-resistant LB plates, picked positive clones and identified using universal primers T7 / T7Ter, amplified the successfully identified single colonies and sent for sequencing. Subsequently, the plasmid amplified by E. coli DH5α that was correctly identified by sequencing was transformed into E. coli BL21 (DE3) competent cells for B2A protein expression. Identification of recombinant plasmids is as follows: Figure 3 shown.
[0129] The successfully constructed ligation product pET-28a-depA-AKRB2 was directly transformed into E. coli DH5α competent cells, spread on kana-resistant LB plates, picked positive clones and identified using universal primers T7 / T7Ter, amplified the successfully identified single colonies and sent them for sequencing. Subsequently, the plasmid amplified by E. coli DH5α with correct sequencing identification was transformed into E. coli BL21 (DE3) competent cells for APB protein expression.
[0130] The polynucleotide encoding the bifunctional enzyme (B2A) has the nucleotide sequence shown in SEQ ID NO:5; the B2A protein has the amino acid sequence shown in SEQ ID NO:6.
[0131] Polynucleotide of bifunctional enzyme (B2A) (SEQ ID NO: 5)
[0132] ATGCATCATCACCATCACCAT AGCGAACCGAACGCGGCTCTGGCGGGTCAGTTCAAAATCGGTGGCGATCTGACCATCAACCGTCTGGGTTTCGGTGCAATGCGTATCACCGGTGAAGGTATCTGGGGTCAGCCGAAAGATGTTGAAGAAGCGCGTCGTGTTCTGCGTCGTCTGAAAGCGCTGGGTGTAAACTTCGTTGACACCGCGGAAAGCTACGGCCCGGAAGTTTCTGAACAGCTGATCGCGGATGAACTGTACCCGTACGATGGTTTCGTTATCGCGACCAAAGCAGGCCTGCAGCGTCCGGGTCCGAACCACTGGGTTCAGGATGGCCGCCCGGAAGTTCTGCGCCGTGGTCTGGAAGCGAGCCTGAAACGTCTGAAAGTTGAACGTATCGACCTGTGGCAGCTGCACCGCATCGATAGCAAAGTTCCGCGTGATGAACAGTTCGCAGCGATCGCAGGCTTCGTTAAAGACGGTCTGGTTCGTCACGTTGGCCTGAGCGAAGTTACCGTGGAAGAAATCGAAGCAGCGCAGAAATACTTCCCGGTTGCTACCATCCAGAACCGCTACAACCTGTTCGACCGTGCGAGCGAAGAAGAACTGGAGTTCTGCGAAGCGAACGCGATCGGCTTCATCCCGTGGGCGCCCCTGGCGTCTGGTCGTGTGGGTGGCCGTCCGGTGCTGGAAGCGGTTGCGCAGCGTCATGGTGCATCTCCGGGTCAAATTGCTCTGGCTTGGATGTTAAAACGTTCTCCGGTTATCTTACCGATTCCGGGTACCGGTAAAGTTGCTCATCTGGAAGAAAACGTTGCTGCCGCTGGTATTACCCTGTCTGAAGGTGATATGGCTGAACTGGAAGGCGCTTCC GGTGGTGGTGGATCGGGCGGAGGGGGATCATAA
[0133] Amino acid sequence of bifunctional enzyme (B2A) (SEQ ID NO: 6)
[0134] M HHHHHH SEPNAALAGQFKIGGDLTINRLGFGAMRITGEGIWGQPKDVEEARRVLRRLKALGVNFVDTAESYGPEVSEQLIADELYPYDGFVIATKAGLQRPGPNHWVQDGRPEVLRRGLEASLKRLKVERIDLWQLHRIDSKVPRDEQFAAIAGFVKDGLVRHVGLSEVTVEEIEAAQKYFPVATIQNRYNLFDRASEEELEFCEANAIGFIPWAPLASGRVGGRPVLEAVAQRHGASPGQIALAWMLKRSPVILPIPGTGKVAHLEENVAAAGITLSEGDMAELEGAS GGGGSG GGGS-
[0135] The polynucleotide encoding the bifunctional enzyme (APB) has the nucleotide sequence shown in SEQ ID NO:7; the APB protein has the amino acid sequence shown in SEQ ID NO:8.
[0136] Polynucleotide of bifunctional enzyme (APB) (SEQ ID NO:7)
[0137]
[0138] Amino acid sequence of bifunctional enzyme (APB) (SEQ ID NO: 8)
[0139] M HHHHHH SAPAFAQHADGAAAETAAPGQSAIENFQPVTAEDLAGGNAANWPILRGNYQGWGYTQLDQINKDNVGQLQLAWARTMEPGSNEGSAIAYNGVVFLGNANDVVQAIDGKTGNLIWEYRRKLPPASKFINSLGAAKRSIALFGDKVYFVSWDNFVVALDAKTGKLAWETNRGQGVEEGVSNSSGPIVVDGVVIAGSTCQYSGFGCYVTGTDAESGEELWRNTFIPRPGEEGDDTWGGAPYENRWMTGAWGQITYDPELDLVYYGSTGAGPASEVQRGTEGGTLAGTNTRFAVKPKTGEVVWKHQTLPRDNWDSECTFEMMVVSTTVNPDAGADGMMSVGANVPRGETRKVLTGVPCKTGVAWQFDAETGDYFWSKATVEQNSIASIDDKGLVTVNEDMILKEPGKDYNYCPTFLGGRDWPSAGYLPKSNLYVIPLSNACYDLKARTTEATPADVYNTDSTVKLAPGKTNMGRVDAIDVATGATKWSFETEAALYDPVMTTAGDLVFVGSTDRMFRALDAETGKEVWSTRLPGAISGYTTSYSIDGRQYVAVVAGGSLGTGFFKAAVPGVDAVQGGNGIYVFALPEAK GSGATNFS LLKQAGDVEENPGP SEPNAALAGQFKIGGDLTINRLGFGAMRITGEGIWGQPKDVEEARRVLRRLKALGVNFVDTAESYGPEVSEQLIADELYPYDGFVIATKAGLQRPGPNHWVQDGRPEVLRRGLEASLKRLKVERIDLWQLHRIDSKVPRDEQFAAIAGFVKDGLVRHVGLSEVTVEEIEAAQKYFPVATIQNRYNLFDRASEEELEFCEANAIGFIPWAPLASGRVGGRPVLEAVAQRHGASPGQIALAWMLKRSPVILPIPGTGKVAHLEENVAAAGITLSEGDMAELEGAS-
[0140] Example 2: Expression of B2A and APB proteins
[0141] Protein induction expression: After streaking the successfully constructed BL21(DE3) / pET-22b-AKRB2-depA on an LB plate containing ampicillin (Amp), the activated strain was cultured at 37°C overnight. The positive monoclonal clone was picked and transferred to 500 μL of LB liquid medium containing ampicillin (Amp), cultured at 37°C in a shaker (220 rpm / min) for 5 hours, and then transferred to 10 mL of LB liquid medium containing ampicillin (Amp) at a ratio of 1:100, and cultured at 37°C in a shaker (220 rpm / min) until the OD 600 When the pH reached 0.6-0.8, IPTG was added to make the final concentration 0.4 mM, and the mixture was placed in a 20°C shaker (120 rpm) for 12 h of induction culture.
[0142] After streaking the successfully constructed BL21(DE3)-depA-AKRB2 on an LB plate containing kana, the activated strain was cultured overnight at 37°C. The positive single clone was picked and transferred to 500 μL of LB liquid medium containing kana, cultured at 37°C in a shaker (220 rpm / min) for 5 h, and then transferred to 10 mL of LB liquid medium containing ampicillin (Amp) at a ratio of 1:100, and cultured at 37°C in a shaker (220 rpm / min) until the OD 600 When the pH reached 0.6-0.8, IPTG was added to make the final concentration 0.2 mM, and the mixture was placed in a 20°C shaker (120 rpm) for 12 h of induction culture.
[0143] Protein lysis and purification: The induced bacterial solution was centrifuged to collect the cells, resuspended with 50mM Tris-HCl at a ratio of 1:10, and the protease inhibitor PMSF was added at a final concentration of 0.1mM. The E. coli cells were fully lysed by ultrasonic disruption. The broken liquid was placed in a 4℃ centrifuge and centrifuged at 12000rpm / min for 30min, and the supernatant was collected. 25μL of the supernatant was mixed with 5μL of 6×Loading Buffer, incubated at 95℃ for 10min, and then placed in a 4℃ centrifuge and centrifuged at 12000rpm / min for 10min. The remaining supernatant was passed through a Ni-NTA column (1mL filler column), and 2mL of Binding / Washbuffer was used to elute the impurities through the column. This step was repeated 5 times, and then the protein with 6×His tag was eluted with Elution buffer to obtain the purified protein. Take 25 μL of purified protein and mix with 5 μL of 6× Loading Buffer, incubate at 95℃ for 10 min, and then centrifuge at 12000 rpm / min for 10 min in a 4℃ centrifuge. The denatured protein was detected by SDS-PAGE electrophoresis and stained with Coomassie Brilliant Blue, and the protein bands were analyzed after decolorization.
[0144] The results showed that the B2A protein was successfully expressed in E. coli BL21 (DE3) cells, and a single target protein band was obtained after nickel column purification ( Figure 4 ).
[0145] APB protein was successfully expressed in E. coli BL21 (DE3) cells. The expression level was analyzed and compared with the expression of single depA protein, it was increased by 5.6 times ( Figure 5 ).
[0146] Example 3: Catalytic effect of B2A crude enzyme solution on DON
[0147] The supernatant crude enzyme solution obtained by ultrasonic disruption was reacted with DON in a buffer solution, wherein 88 μl crude enzyme solution, 1 μl (100 mM) PQQ, 1 μl (0.1 M) CaCl2, and 10 μl (100 ppm) DON were added to 100 μl reaction system, and 88 μl 50 mM Tris-HCl, 1 μl (100 mM) PQQ, 1 μl (0.1 M) CaCl2, and 10 μl DON were added to the control group. The above reaction system was placed in a 40°C water bath for 4 hours and then incubated at 98°C for 2 minutes to terminate the reaction.
[0148] High performance liquid chromatography (HPLC-UV) was used to detect DON and degradation products in the solution. The liquid chromatography system was a Thermo UltiMate3000 system (Thermo Fisher Scientific, USA), and the chromatographic column was an Agilent ZorbaxExtend-C18 column (100 mm×3 mm, 3.5 μm). The column temperature was 30°C, and the sample injection volume was 40 μL. The mobile phase was methanol / 0.2% formic acid water (10 / 90, v / v), and the mobile phase flow rate was 0.5 mL / min. The running time was 15 min, and the UV detection wavelength was 218 nm.
[0149] The HPLC test results showed that the retention time of DON was 10.01 min. After the crude enzyme reaction, no DON was detected at this retention time, indicating that 100% degradation of DON could be achieved ( FIG. 6 ).
[0150] Example 4: High-resolution mass spectrometric identification of DON degradation products
[0151] The structure of the DON degradation product of the bifunctional enzyme B2A was identified using TripleTOF 6600 high-resolution LC-MS. DON and its degradation products are shown in Figure 7.
[0152] As shown in FIG7 , 3-epi-DON and 3-keto-DON can be detected in the degradation products, respectively, so the degradation effect of the bifunctional enzyme can be confirmed.
[0153] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for a person of ordinary skill in the art, several variations and improvements can be made without departing from the concept of the present invention, and these all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims. At the same time, all the documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference separately.
Claims
1. A method for degrading vomitoxin, characterized in that: The method comprises: (1) connecting a dehydrogenase fragment and an aldehyde-keto reductase fragment to form a bifunctional enzyme with synergistic effects; (2) Using the bifunctional enzyme with synergistic effect described in (1) or a system containing the enzyme to treat vomitoxin or an object containing the vomitoxin, the vomitoxin is degraded into 3-keto-DON and 3-epi-DON.
2. The method according to claim 1, characterized in that (a) the bifunctional enzyme comprises, from the amino terminus to the carboxyl terminus, the dehydrogenase fragment and the aldehyde-keto reductase fragment; preferably, the two are connected by a connecting peptide; or (b) the bifunctional enzyme comprises, from the amino terminus to the carboxyl terminus, the aldehyde-keto reductase fragment and the dehydrogenase fragment; preferably, the two are connected by a connecting peptide; More preferably, the connecting peptide comprises a flexible connecting protein.
3. The method according to claim 2, characterized in that (a), the amino acid sequence of the dehydrogenase fragment is as shown at positions 1 and 8 to 592 in SEQ ID NO:8; the amino acid sequence of the aldehyde-keto reductase fragment is as shown at positions 615 to 897 in SEQ ID NO:8; preferably, the amino acid sequence of the connecting peptide is as shown at positions 593 to 614 in SEQ ID NO:7; or In (b), the amino acid sequence of the dehydrogenase fragment is as shown at positions 1 and 8 to 290 in SEQ ID NO:6; the amino acid sequence of the aldehyde-keto reductase fragment is as shown at positions 301 to 885 in SEQ ID NO:6; preferably, the amino acid sequence of the connecting peptide is as shown at positions 291 to 300 in SEQ ID NO:
6.
4. The method according to claim 1 or 2, characterized in that: The amino acid sequence of the bifunctional enzyme is shown in SEQ ID NO: 8 or SEQ ID NO: 6; Preferably, the bifunctional enzyme is encoded by a nucleic acid molecule having a nucleotide sequence as shown in SEQ ID NO:7 or SEQ ID NO:5; More preferably, the amino acid sequence of the bifunctional enzyme is as shown in SEQ ID NO:
8.
5. A bifunctional enzyme with synergistic effects, comprising the following proteins linked to each other: a dehydrogenase fragment, and an aldehyde-keto reductase fragment, both of which are operably linked.
6. The synergistic bifunctional enzyme according to claim 5, characterized in that: (a) the bifunctional enzyme comprises, from the amino terminus to the carboxyl terminus, the dehydrogenase fragment and the aldehyde-keto reductase fragment; preferably, the two are connected by a connecting peptide; or (b) the bifunctional enzyme comprises, from the amino terminus to the carboxyl terminus, the aldehyde-keto reductase fragment and the dehydrogenase fragment; preferably, the two are connected by a connecting peptide; More preferably, the connecting peptide comprises a flexible connecting protein.
7. The synergistic bifunctional enzyme according to claim 6, characterized in that: (a), the amino acid sequence of the dehydrogenase fragment is as shown at positions 1 and 8 to 592 in SEQ ID NO:8; the amino acid sequence of the aldehyde-keto reductase fragment is as shown at positions 615 to 897 in SEQ ID NO:8; preferably, the amino acid sequence of the connecting peptide is as shown at positions 593 to 614 in SEQ ID NO:7; or (b), the amino acid sequence of the dehydrogenase fragment is as shown at positions 1 and 8 to 290 in SEQ ID NO:6; the amino acid sequence of the aldehyde-keto reductase fragment is as shown at positions 301 to 885 in SEQ ID NO:6; preferably, the amino acid sequence of the connecting peptide is as shown at positions 291 to 300 in SEQ ID NO:6; More preferably, the amino acid sequence of the bifunctional enzyme is as shown in SEQ ID NO:
8.
8. A nucleic acid molecule encoding the synergistic bifunctional enzyme according to any one of claims 5 to 7; preferably, the nucleotide sequence of the nucleic acid is as shown in SEQ ID NO:7 or SEQ ID NO:
5.
9. A vector comprising the nucleic acid molecule according to claim 8.
10. A genetically engineered cell, said cell comprising the vector according to claim 9 or a cell in which the nucleic acid molecule according to claim 8 is integrated into its genome.
11. A method for preparing the bifunctional enzyme with synergistic effect as claimed in any one of claims 5 to 7, comprising: (1) culturing the genetically engineered cell according to claim 10; as well as (2) Expressing and isolating the bifunctional enzyme with synergistic effect as claimed in any one of claims 5 to 7.
12. Use of the synergistic bifunctional enzyme according to any one of claims 5 to 7 for: Degradation of DON; or A composition for degrading vomitoxin is prepared.
13. A composition for degrading vomitoxin, characterized in that: The composition contains: (i) the bifunctional enzyme having synergistic effect according to any one of claims 5 to 7; and (ii) a biologically acceptable carrier.
14. A kit for degrading vomitoxin, characterized in that: It contains the synergistic bifunctional enzyme according to any one of claims 5 to 7; or it contains the composition according to claim 13.
